Kardigan readies Nasdaq IPO to back three cardio drugs

endpts.com·May 27, 2026

Kardigan is preparing for a Nasdaq IPO to fund the development of three cardiovascular drugs, capitalizing on growing investor interest in clinical-stage biotech companies.

Kardigan's upcoming Nasdaq IPO highlights growing investor interest in clinical-stage biotech firms, particularly those focused on cardiovascular drugs. This move signals an opportune time for professionals in healthtech and biotech to explore investment or partnership opportunities with companies preparing for public offerings in the cardiovascular space.

Want more content like this?

twixb tracks your favorite blogs and social media, filters by keywords, and delivers personalized key learnings — straight to your inbox.

Create Your Own →Explore Newsfeeds

More from Healthtech & Biotech News

Recent stories curated alongside this one.

mobihealthnews.com
Epic integrates firearm injury risk screening tool from Northwell Health
Northwell Health has integrated a firearm injury risk screening tool into Epic's electronic health record system, aimed at identifying patients at risk of firearm injuries, providing them with gun locks, and referring them to intervention services. This initiative is part of a broader effort to enhance patient safety and prevent gun violence through real-time clinical interventions.
endpts.com
Shionogi wins US approval for first pill to prevent Covid following exposure
Shionogi has received FDA approval for its oral antiviral pill designed to prevent COVID-19 in both adults and children following exposure, marking a significant advancement in COVID-19 treatment options.
fiercebiotech.com
<a href="https://www.fiercebiotech.com/biotech/asco-2026-paradigm-shift-rare-gut-cancer-looms" hreflang="en">At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms</a>
At ASCO 2026, GSK introduced velzatinib, a new tyrosine kinase inhibitor aimed at treating gastrointestinal stromal tumors (GISTs), which could potentially redefine standard care by effectively targeting both primary and secondary mutations in the c-KIT enzyme. Preliminary results showed promising tumor shrinkage rates in patients, positioning velzatinib as a potential improvement over existing treatments like Gleevec and Sutent.
statnews.com
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
Recent data presented at the American Society of Clinical Oncology (ASCO) meeting highlights significant advancements in cancer treatment, including the pancreatic cancer drug daraxonrasib, which improves median overall survival by 60% compared to standard chemotherapy. Additionally, the meeting showcased the growing influence of China's biotechnology sector, marking a notable shift in global drug development dynamics.
statnews.com
STAT+: A turning point for pancreatic cancer patients
Revolution Medicines is making significant strides in pancreatic cancer treatment with the early access rollout of their experimental drug, daraxonrasib, which has shown promising results at the ASCO conference. Additionally, Eli Lilly announced two deals in China and Akeso's lung cancer therapy continues to exceed expectations, marking a notable period in biotech advancements.

Browse all Healthtech & Biotech News →

Kardigan readies Nasdaq IPO to back three cardio drugs

Want more content like this?

More from Healthtech & Biotech News

Epic integrates firearm injury risk screening tool from Northwell Health

Shionogi wins US approval for first pill to prevent Covid following exposure

<a href="https://www.fiercebiotech.com/biotech/asco-2026-paradigm-shift-rare-gut-cancer-looms" hreflang="en">At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms</a>

STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more

STAT+: A turning point for pancreatic cancer patients